The vulnerable atherosclerotic plaque
Tóm tắt
Từ khóa
Tài liệu tham khảo
Aikawa, 2001, Vascular inflammation and activation: new targets for lipid lowering, Eur Heart J Suppl, 3, B3, 10.1016/S1520-765X(01)90051-3
Libby, 2002, Stabilization of atherosclerotic plaques: new mechanisms and clinical targets, Nat Med, 8, 1257, 10.1038/nm1102-1257
Stary, 1989, Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults, Arteriosclerosis, 9, I19
Aikawa, 1993, Human smooth muscle myosin heavy chain isoforms as molecular markers for vascular development and atherosclerosis, Circ Res, 73, 1000, 10.1161/01.RES.73.6.1000
Munro, 1988, The pathogenesis of atherosclerosis: atherogenesis and inflammation, Lab Invest, 58, 249
Libby, 2001, Evolution and stabilization of vulnerable atherosclerotic plaques, Jpn Circ J, 65, 473, 10.1253/jcj.65.473
Stamler, 1988, Dietary cholesterol and human coronary heart disease. The epidemiologic evidence, Arch Pathol Lab Med, 112, 1032
Libby, 2000, Cholesterol and atherosclerosis, Biochim Biophys Acta, 1529, 299, 10.1016/S1388-1981(00)00161-X
Anitschkow, 1983, On experimental cholesterin steatosis and its significance in the origin of some pathological processes (1913), Arteriosclerosis, 3, 178, 10.1161/01.ATV.3.2.178
Vesselinovitch, 1988, Animal models and the study of atherosclerosis, Arch Pathol Lab Med, 112, 1011
Armstrong, 1990, Animal models of atherosclerosis, Atherosclerosis, 85, 15, 10.1016/0021-9150(90)90178-L
Aikawa, 2000, Rabbit models of atherosclerosis, 175
Steinberg, 1989, Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity, N Engl J Med, 320, 915
Miller, 2003, Oxidized low density lipoprotein and innate immune receptors, Curr Opin Lipidol, 14, 437, 10.1097/00041433-200310000-00004
Berliner, 1995, Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics, Circulation, 91, 2488, 10.1161/01.CIR.91.9.2488
Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Circulation 2003;108:1912–6, 2034–2040.
Haberland, 1988, Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits, Science, 241, 215, 10.1126/science.2455346
Yla-Herttuala, 1989, Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man, J Clin Invest, 84, 1086, 10.1172/JCI114271
Aikawa, 2002, Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma, Circulation, 106, 1390, 10.1161/01.CIR.0000028465.52694.9B
Quinn, 1987, Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis, Proc Natl Acad Sci USA, 84, 2995, 10.1073/pnas.84.9.2995
Cushing, 1990, Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells, Proc Natl Acad Sci USA, 87, 5134, 10.1073/pnas.87.13.5134
Rosenfeld, 1990, Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits, Arteriosclerosis, 10, 680, 10.1161/01.ATV.10.5.680
Gordon, 1990, Cell proliferation in human coronary arteries, Proc Natl Acad Sci USA, 87, 4600, 10.1073/pnas.87.12.4600
Aikawa, 2001, An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro, Circulation, 103, 276, 10.1161/01.CIR.103.2.276
Sakai, 2000, Macrophage proliferation in atherosclerosis, Curr Opin Lipidol, 11, 503, 10.1097/00041433-200010000-00008
Collins, 2001, NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?, J Clin Invest, 107, 255, 10.1172/JCI10373
Kodama, 1990, Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils, Nature, 343, 531, 10.1038/343531a0
Griendling, 1997, Oxidative stress and cardiovascular disease, Circulation, 96, 3264
Davies, 1985, Plaque fissuring—the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina, Br Heart J, 53, 363, 10.1136/hrt.53.4.363
Hackett, 1988, Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe, Eur Heart J, 9, 1317, 10.1093/oxfordjournals.eurheartj.a062449
Ambrose, 1988, Angiographic progression of coronary artery disease and the development of myocardial infarction, J Am Coll Cardiol, 12, 56, 10.1016/0735-1097(88)90356-7
Davies, 1993, Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content, Br Heart J, 69, 377, 10.1136/hrt.69.5.377
van der Wal, 1994, Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology, Circulation, 89, 36, 10.1161/01.CIR.89.1.36
Moreno, 1994, Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture, Circulation, 90, 775, 10.1161/01.CIR.90.2.775
Visse, 2003, Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry, Circ Res, 92, 827, 10.1161/01.RES.0000070112.80711.3D
Chase, 2003, Regulation of matrix metalloproteinase (matrixin) genes in blood vessels: a multi-step recruitment model for pathological remodelling, J Vasc Res, 40, 329, 10.1159/000072697
Ducharme, 2000, Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction, J Clin Invest, 106, 55, 10.1172/JCI8768
Rabkin, 2001, Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves, Circulation, 104, 2525, 10.1161/hc4601.099489
Brinckerhoff, 2002, Matrix metalloproteinases: a tail of a frog that became a prince, Nat Rev Mol Cell Biol, 3, 207, 10.1038/nrm763
Jones, 2003, Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome, Cardiovasc Res, 59, 812, 10.1016/S0008-6363(03)00516-9
Galis, 1994, Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques, J Clin Invest, 94, 2493, 10.1172/JCI117619
Sukhova, 1999, Evidence of increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques, Circulation, 99, 2503, 10.1161/01.CIR.99.19.2503
Herman, 2001, Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling, Circulation, 104, 1899, 10.1161/hc4101.097419
Burke, 1997, Coronary risk factors and plaque morphology in men with coronary disease who died suddenly, N Engl J Med, 336, 1276, 10.1056/NEJM199705013361802
Lee, 1995, Human vascular smooth muscle cell–monocyte interactions and metalloproteinase secretion in culture, Arterioscler Thromb Vasc Biol, 15, 2284, 10.1161/01.ATV.15.12.2284
Lee, 1997, The unstable atheroma, Arterioscler Thromb Vasc Biol, 17, 1859, 10.1161/01.ATV.17.10.1859
Loree, 1992, Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels, Circ Res, 71, 850, 10.1161/01.RES.71.4.850
Loree, 1994, Mechanical properties of model atherosclerotic lesion lipid pools, Arterioscler Thromb, 14, 230, 10.1161/01.ATV.14.2.230
Wilcox, 1989, Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque, Proc Natl Acad Sci USA, 86, 2839, 10.1073/pnas.86.8.2839
Lupu, 1993, Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries, Arterioscler Thromb, 13, 1090, 10.1161/01.ATV.13.7.1090
Heinecke, 2002, Oxidized amino acids: culprits in human atherosclerosis and indicators of oxidative stress, Free Radic Biol Med, 32, 1090, 10.1016/S0891-5849(02)00792-X
Sugiyama, 2001, Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes, Am J Pathol, 158, 879, 10.1016/S0002-9440(10)64036-9
Rajagopalan, 1996, Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability, J Clin Invest, 98, 2572, 10.1172/JCI119076
Rajavashisth, 1999, Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase, J Biol Chem, 274, 11924, 10.1074/jbc.274.17.11924
Kume, 1992, Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells, J Clin Invest, 90, 1138, 10.1172/JCI115932
Khan, 1995, Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells, J Clin Invest, 95, 1262, 10.1172/JCI117776
Li, 1993, An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium, Arterioscler Thromb, 13, 197, 10.1161/01.ATV.13.2.197
Cybulsky, 2001, A major role for VCAM-1, but not ICAM-1, in early atherosclerosis, J Clin Invest, 107, 1255, 10.1172/JCI11871
Gu, 1998, Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice, Mol Cell, 2, 275, 10.1016/S1097-2765(00)80139-2
Boring, 1998, Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis, Nature, 394, 894, 10.1038/29788
Tsao, 1994, Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by l-arginine, Circulation, 89, 2176, 10.1161/01.CIR.89.5.2176
De Caterina, 1995, Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines, J Clin Invest, 96, 60, 10.1172/JCI118074
Khan, 1996, Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells, Proc Natl Acad Sci USA, 93, 9114, 10.1073/pnas.93.17.9114
Tsao, 1997, Nitric oxide regulates monocyte chemotactic protein-1, Circulation, 96, 934, 10.1161/01.CIR.96.3.934
Oemar, 1998, Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis, Circulation, 97, 2494, 10.1161/01.CIR.97.25.2494
Liao, 1995, Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase, J Biol Chem, 270, 319, 10.1074/jbc.270.1.319
Farb, 1996, Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death, Circulation, 93, 1354, 10.1161/01.CIR.93.7.1354
Schneiderman, 1992, Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries, Proc Natl Acad Sci USA, 89, 6998, 10.1073/pnas.89.15.6998
Gotto, 2001, Lipid-lowering trials, 126
Libby, 2003, Mechanisms of plaque stabilization with statins, Am J Cardiol, 91, 4B, 10.1016/S0002-9149(02)03267-8
Brown, 1993, Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease, Circulation, 87, 1781, 10.1161/01.CIR.87.6.1781
Libby, 1995, Molecular bases of the acute coronary syndromes, Circulation, 91, 2844, 10.1161/01.CIR.91.11.2844
Small, 1988, George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry, Arteriosclerosis, 8, 103, 10.1161/01.ATV.8.2.103
Wissler, 1990, Can atherosclerotic plaques regress? Anatomic and biochemical evidence from nonhuman animal models, Am J Cardiol, 65, 33F, 10.1016/0002-9149(90)91253-3
Liao, 2002, Isoprenoids as mediators of the biological effects of statins, J Clin Invest, 110, 285, 10.1172/JCI0216421
Aikawa, 1998, Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization, Circulation, 97, 2433, 10.1161/01.CIR.97.24.2433
Aikawa, 1999, Dietary lipid lowering reduces tissue factor expression in rabbit atheroma, Circulation, 100, 1215, 10.1161/01.CIR.100.11.1215
Aikawa, 1998, Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma, Circ Res, 83, 1015, 10.1161/01.RES.83.10.1015
Kockx, 1998, Cell composition, replication, and apoptosis in atherosclerotic plaques after 6 months of cholesterol withdrawal, Circ Res, 83, 378, 10.1161/01.RES.83.4.378
Crisby, 2001, Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization, Circulation, 103, 926, 10.1161/01.CIR.103.7.926
Fukumoto, 2001, Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits, Circulation, 103, 993, 10.1161/01.CIR.103.7.993
Ohara, 1995, Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production, Circulation, 92, 898, 10.1161/01.CIR.92.4.898
Palinski, 1995, Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis, Arterioscler Thromb Vasc Biol, 15, 1569, 10.1161/01.ATV.15.10.1569
Cyrus, 1999, Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice, J Clin Invest, 103, 1597, 10.1172/JCI5897
Salonen, 1992, Autoantibody against oxidised LDL and progression of carotid atherosclerosis, Lancet, 339, 883, 10.1016/0140-6736(92)90926-T
O'Brien, 1993, Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis, J Clin Invest, 92, 945, 10.1172/JCI116670
Brogi, 1993, Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and nonatherosclerotic arteries. Association of acidic FGF with plaque microvessels and macrophages, J Clin Invest, 92, 2408, 10.1172/JCI116847
Tenaglia, 1998, Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina, Am Heart J, 135, 10, 10.1016/S0002-8703(98)70336-9
Celletti, 2001, Vascular endothelial growth factor enhances atherosclerotic plaque progression, Nat Med, 7, 425, 10.1038/86490
Moulton, 1999, Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice, Circulation, 99, 1726, 10.1161/01.CIR.99.13.1726
Blake, 2003, C-reactive protein and other inflammatory risk markers in acute coronary syndromes, J Am Coll Cardiol, 41, 37S, 10.1016/S0735-1097(02)02953-4
Colli, 1997, Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis, Arterioscler Thromb Vasc Biol, 17, 265, 10.1161/01.ATV.17.2.265
Bellosta, 1998, HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages, Arterioscler Thromb Vasc Biol, 18, 1671, 10.1161/01.ATV.18.11.1671
Guijarro, 1998, 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture, Circ Res, 83, 490, 10.1161/01.RES.83.5.490
Bourcier, 2000, HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells, Arterioscler Thromb Vasc Biol, 20, 556, 10.1161/01.ATV.20.2.556
Sakai, 1997, HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein, Atherosclerosis, 133, 51, 10.1016/S0021-9150(97)00118-4
Negre-Aminou, 1997, Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types, Biochim Biophys Acta, 1345, 259, 10.1016/S0005-2760(96)00184-1
Laufs, 1998, Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase, J Biol Chem, 273, 24266, 10.1074/jbc.273.37.24266
Hernandez-Perera, 2000, Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells, Circ Res, 87, 616, 10.1161/01.RES.87.7.616
Feron, 2001, Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance, Circulation, 103, 113, 10.1161/01.CIR.103.1.113
Kureishi, 2000, The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals, Nat Med, 6, 1004, 10.1038/79510
Yoshida, 2001, Hmg-CoA reductase inhibitor modulates monocyte–endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism, Arterioscler Thromb Vasc Biol, 21, 1165, 10.1161/hq0701.092143
Eto, 2002, Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways, Circulation, 105, 1756, 10.1161/01.CIR.0000015465.73933.3B
Essig, 1998, 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins, Circ Res, 83, 683, 10.1161/01.RES.83.7.683
Weis, 2002, Statins have biphasic effects on angiogenesis, Circulation, 105, 739, 10.1161/hc0602.103393
Urbich, 2002, Double-edged role of statins in angiogenesis signaling, Circ Res, 90, 737, 10.1161/01.RES.0000014081.30867.F8
Walter, 2002, Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells, Circulation, 105, 3017, 10.1161/01.CIR.0000018166.84319.55
Egashira, 1994, Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia, Circulation, 89, 2519, 10.1161/01.CIR.89.6.2519
Treasure, 1995, Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease, N Engl J Med, 332, 481, 10.1056/NEJM199502233320801
Anderson, 1995, The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion, N Engl J Med, 332, 488, 10.1056/NEJM199502233320802
Wilson, 2001, Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering, Arterioscler Thromb Vasc Biol, 21, 122, 10.1161/01.ATV.21.1.122
Tsunekawa, 2001, Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days, Circulation, 104, 376, 10.1161/hc2901.094094
Wassmann, 2003, Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function, Circ Res, 93, e98, 10.1161/01.RES.0000099503.13312.7B
Tamai, 1997, Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans, Circulation, 95, 76, 10.1161/01.CIR.95.1.76
Shimizu, 2003, Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins, Circulation, 108, 2113, 10.1161/01.CIR.0000092949.67153.74
Ridker, 1998, Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators, Circulation, 98, 839, 10.1161/01.CIR.98.9.839
Ridker, 2001, Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia, Circulation, 103, 1191, 10.1161/01.CIR.103.9.1191
Law, 2003, Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis, BMJ, 326, 1423, 10.1136/bmj.326.7404.1423
Kinlay, 2002, Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia, Am J Cardiol, 89, 1205, 10.1016/S0002-9149(02)02306-8
Taylor, 2002, ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness, Circulation, 106, 2055, 10.1161/01.CIR.0000034508.55617.65
van de Ree, 2003, Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus, Atherosclerosis, 166, 129, 10.1016/S0021-9150(02)00316-7
Kinlay, 2003, High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study, Circulation, 108, 1560, 10.1161/01.CIR.0000091404.09558.AF
Weiss, 2001, Angiotensin II and atherosclerosis, Am J Cardiol, 87, 25C, 10.1016/S0002-9149(01)01539-9
Bocan, 2000, The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits, Arterioscler Thromb Vasc Biol, 20, 70, 10.1161/01.ATV.20.1.70
Perrey, 2001, Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis, Atherosclerosis, 155, 359, 10.1016/S0021-9150(00)00599-2
Ziouzenkova, 2002, Peroxisome proliferator-activated receptors, Curr Atheroscler Rep, 4, 59, 10.1007/s11883-002-0063-x
Danenberg, 2003, Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice, Circulation, 108, 512, 10.1161/01.CIR.0000085568.13915.1E
Fayad, 2001, Clinical imaging of the high-risk or vulnerable atherosclerotic plaque, Circ Res, 89, 305, 10.1161/hh1601.095596